Emergent BioSolutions (EBS) Cash from Operations Growth (3y) (2013 - 2026)

Emergent BioSolutions (EBS) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 34.90%
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -9.94%
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 7.32%
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 46.81%
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 27.85%
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -98.15%
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn 111.22%
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 4.87%
10 Emergent BioSolutions 412.09 Mn 250.59 Mn 84.10 Mn 43.15%

Historic Data

Download Data
DateValue
Mar 31, 2026 43.15%
Dec 31, 2025 -5.75%
Sep 30, 2025 68.56%
Jun 30, 2025 106.62%
Mar 31, 2025 33.04%
Dec 31, 2024 -30.91%
Sep 30, 2024 109.57%
Jun 30, 2024 53.25%
Mar 31, 2024 -142.58%
Dec 31, 2023 -49.28%
Sep 30, 2023 -17.07%
Jun 30, 2023 -42.51%
Mar 31, 2023 -73.06%
Dec 31, 2022 -8.74%
Sep 30, 2022 -187.93%
Jun 30, 2022 24.19%
Mar 31, 2022 -33.06%
Dec 31, 2021 58.46%
Sep 30, 2021 -54.22%
Jun 30, 2021 -41.92%